New schizophrenia drugs no better than generic

The American Journal of Psychiatry has published new research that supports the argument that the $10 billion a year spent on a new wave of schizophrenia drugs is largely being wasted. Zyprexa, Seroquel and Risperdal--which have captured the market in the field--work no better than an older and much cheaper generic drug. Using the generic perphenazine, for example, would be $300 to $600 a month cheaper per patient than the prescription drugs. The authors of the study, though, aren't calling for patients to be switched over immediately. Many of these drugs are prescribed in a hit-or-miss approach and patients who are benefiting from their therapies should stay on them. In many cases, the effectiveness of one of these therapies wears off after a relatively short time, marking a good point at which the generic could be prescribed.

- read the report on the study from The Washington Post

Ed. Note: Corrected the figure. Thanks for the comment!

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.